Vanda Pharmaceuticals Inc.
Common Stock · USD · NASDAQ
Price
$6.65
Cap
$34.65B
Earnings
—
30d Trend
-2.2%
94% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 52×Macro 0.99 (−1%)=51
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 80%
BRAIN47 HORIZON ANALYSIS
6-9 month opportunity — emerging trend
BRAIN47'S ASSESSMENT
I rate Vanda Pharmaceuticals Inc. at 51/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 88/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.
PAST PERFORMANCE
1 MONTH
-5.6%
3 MONTHS
-27.5%
12 MONTHS
+49.9%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
6-9 month opportunity — emerging trend. Momentum (88) and Technical (51) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 94%. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.